title: 24 weeks of interferon-ribavirin therapy should not routinely be given to all hepatitis C patients.
authors.forename: D J
authors.initials: DJ
authors.lastname: van Leeuwen
authors.forename: Leland J
authors.initials: LJ
authors.lastname: Yee
authors.forename: Rebecca G
authors.initials: RG
authors.lastname: Langner
mesh_terms: D000998:Antiviral Agents / Q000008:administration & dosage*; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D005260:Female; D005500:Follow-Up Studies; D019698:Hepatitis C, Chronic / Q000175:diagnosis / Q000188:drug therapy*; D006801:Humans; D016898:Interferon-alpha / Q000008:administration & dosage*; D008297:Male; D011446:Prospective Studies; D012254:Ribavirin / Q000008:administration & dosage*; D018570:Risk Assessment; D012680:Sensitivity and Specificity; D013997:Time Factors; D016896:Treatment Outcome; D019562:Viral Load
chemical_list: D000998:Antiviral Agents; D016898:Interferon-alpha; D012254:Ribavirin